Korea approves Keytruda SC, slashing treatment time to 2 minutes Alteogens ALT-B4 enables faster subcutaneous Keytruda launch ...

Merck’s MRK stock has declined 7.3% in the past month despite announcing a solid first-quarter 2026 report on April 30. Merck beat estimates for both earnings and sales. Total r ...

Eli Lilly's Mounjaro has overtaken Keytruda to become the world's top-selling medicine. Its rise highlights booming demand ...

Merck & Co. is slashing $3 billion from its annual spending as it braces for off-brand competition to its cancer drug Keytruda, the best-selling medicine in the world. The drugmaker will cut ...

Merck MRK is focusing on driving its long-term growth with its new products and a promising set of pipeline candidates as its blockbuster PD-L1 inhibitor, Keytruda, faces patent expiration in 2028.

The FDA has approved a new injectable version of cancer drug Keytruda as Merck seeks to protect its market dominance. Here are five things to know: The approved shot is Keytruda Qlex, a widely used ...

Mounjaro surpassed Keytruda as the world’s top-selling medicine, driven by soaring global demand for obesity and diabetes treatments.